Picture of Samsung Biologics Co logo

207940 Samsung Biologics Co Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Annual cashflow statement for Samsung Biologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line393,589798,056857,6911,083,3161,784,352
Depreciation
Amortisation
Non-Cash Items187,832289,411312,968323,396553,547
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-288,614-442,6845,787-346,558-723,729
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities454,596953,0481,666,2291,659,2552,247,807
Capital Expenditures-421,152-1,009,226-1,105,325-1,377,526-1,475,074
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-512,337-2,097,252-460,981133,749-387,352
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-933,489-3,106,477-1,566,305-1,243,776-1,862,426
Financing Cash Flow Items-12,430-216,417
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities496,6223,000,080-635,050-433,788-620,504
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash18,560843,409-522,88223,284-242,370